论文部分内容阅读
自应用阿霉素以来,恶性淋巴瘤的疗效明显提高,引入COP-BLAMⅢ和MACOP-B等第三代疗法后,使缓解率和生存时间也得到改善,但目前巨大型纵隔型恶性淋巴瘤诱导缓解疗法后,肿瘤残存的患者仍预后不良,尚无有效疗法。本文以东邦大学第1内科自1981年至1991年11年间所经治的406例恶性淋巴瘤中肿瘤长径>6cm的19例纵隔型恶性淋巴瘤为研究对象,观察其预后。19例中男9例,女10例,平均年龄46岁。其中何杰金病(HD)7例,包括混合细胞型2例,结节硬化型5例;非何杰金淋巴瘤(NHL)12例,包括弥漫性大
Since the application of doxorubicin, the efficacy of malignant lymphoma was significantly improved, the introduction of COP-BLAM Ⅲ and MACOP-B and other third-generation therapy, the remission rate and survival time has also been improved, but the current large mediastinal lymphoma induction After remission therapy, patients with residual tumor still have a poor prognosis and no effective treatment. In this paper, Toho University, Department of Internal Medicine from 1981 to 1991, 11 years in the control of 406 cases of malignant lymphoma tumor diameter> 6cm in 19 cases of mediastinal type of malignant lymphoma as the object of study to observe the prognosis. 19 cases of 9 males and 10 females, average age 46 years old. Among them, 7 cases of Hodgkin’s disease (HD), including 2 cases of mixed cell type and 5 cases of nodular sclerosis; 12 cases of non-Hodgkin’s lymphoma (NHL), including diffuse large